EyePoint Pharmaceuticals segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di EyePoint Pharmaceuticals utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
EYPT | EyePoint Pharmaceuticals | -$0.54 | -$0.77 | -$0.85 | -10.39% | $10.52M | $4.59M | $966.00K | -78.93% | 11/05/2025 | |
EYPT | EyePoint Pharmaceuticals | -$0.58 | -$0.75 | -$0.85 | -13.33% | $9.48M | $6.85M | $5.33M | -22.12% | 08/06/2025 | |
EYPT | EyePoint Pharmaceuticals | -$0.55 | -$0.55 | -$0.65 | -18.18% | $11.68M | $8.09M | $24.45M | 202.26% | 05/07/2025 | |
EYPT | EyePoint Pharmaceuticals | -$0.33 | -$0.48 | -$0.64 | -33.33% | $14.03M | $11.02M | $11.59M | 5.15% | 03/05/2025 | |
EYPT | EyePoint Pharmaceuticals | -$0.33 | -$0.55 | -$0.54 | 1.82% | $15.20M | $9.93M | $10.52M | 5.98% | 11/07/2024 | |
EYPT | EyePoint Pharmaceuticals | -$0.57 | -$0.52 | -$0.58 | -11.54% | $9.11M | $9.59M | $9.48M | -1.18% | 08/07/2024 | |
EYPT | EyePoint Pharmaceuticals | -$0.56 | -$0.42 | -$0.55 | -30.95% | $7.68M | $9.92M | $11.68M | 17.78% | 05/08/2024 | |
EYPT | EyePoint Pharmaceuticals | -$1.16 | -$0.49 | -$0.33 | 32.65% | $10.53M | $8.90M | $14.03M | 57.62% | 03/07/2024 | |
EYPT | EyePoint Pharmaceuticals | -$0.49 | -$0.51 | -$0.33 | 35.29% | $10.01M | $7.52M | $15.20M | 102.15% | 11/01/2023 | |
EYPT | EyePoint Pharmaceuticals | -$0.52 | $0.41 | -$0.57 | -239.02% | $11.56M | $79.03M | $9.11M | -88.48% | 08/02/2023 | |
EYPT | EyePoint Pharmaceuticals | -$0.56 | -$0.68 | -$0.56 | 17.65% | $9.29M | $7.43M | $7.68M | 3.41% | 05/03/2023 | |
EYPT | EyePoint Pharmaceuticals | -$0.59 | -$0.61 | -$0.61 | 0.00% | $11.54M | $10.40M | $10.53M | 1.28% | 03/02/2023 | |
EYPT | EyePoint Pharmaceuticals | -$0.58 | -$0.70 | -$0.49 | 30.00% | $9.06M | $10.64M | $10.01M | -5.90% | 11/02/2022 | |
EYPT | EyePoint Pharmaceuticals | -$0.42 | -$0.52 | -$0.52 | 0.00% | $9.01M | $10.87M | $11.56M | 6.39% | 08/03/2022 | |
EYPT | EyePoint Pharmaceuticals | -$0.50 | -$0.58 | -$0.56 | 3.45% | $7.32M | $9.89M | $9.29M | -6.03% | 05/04/2022 | |
EYPT | EyePoint Pharmaceuticals | -$0.10 | -$0.53 | -$0.59 | -11.32% | $4.12M | $9.80M | $11.54M | 17.80% | 03/03/2022 | |
EYPT | EyePoint Pharmaceuticals | -$0.30 | -$0.40 | -$0.58 | -45.00% | $7.49M | $9.84M | $9.06M | -7.94% | 11/03/2021 | |
EYPT | EyePoint Pharmaceuticals | -$1.00 | -$0.43 | -$0.42 | 2.33% | $8.63M | $9.13M | $9.01M | -1.28% | 08/04/2021 | |
EYPT | EyePoint Pharmaceuticals | -$1.10 | -$0.46 | -$0.50 | -8.70% | $2.51M | $7.93M | $7.32M | -7.65% | 05/05/2021 | |
EYPT | EyePoint Pharmaceuticals | -$1.00 | -$0.17 | -$1.00 | -488.24% | $7.21M | $20.44M | $7.13M | -65.11% | 03/04/2021 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-05 | $-0.85 | $-0.77 | -10.4 % |
| Q2 | 2025-08-06 | $-0.85 | $-0.75 | -13.3 % |
| Q1 | 2025-05-07 | $-0.65 | $-0.55 | -18.2 % |
| Q4 | 2025-03-05 | $-0.64 | $-0.48 | -33.3 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-11-05 | $966.00K | $4.59M | -78.9 % |
| Q2 | 2025-08-06 | $5.33M | $6.85M | -22.1 % |
| Q1 | 2025-05-07 | $24.45M | $8.09M | 202.3 % |
| Q4 | 2025-03-05 | $11.59M | $11.02M | 5.15 % |
EyePoint Pharmaceuticals (EYPT) non ha ancora previsto report sulle performance. L'ultimo report sui risultati è stato pubblicato il novembre 5, 2025 per il Q3.
EyePoint Pharmaceuticals (EYPT) non ha ancora in programma alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 5, 2025 per il Q3 e l'EPS effettivo è stato $-0.85, che mancato la stima di $-0.77.
EyePoint Pharmaceuticals (EYPT) non ha ancora pianificato alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il novembre 5, 2025 per il Q3 e i ricavi effettivi sono stati $966K, che mancato la stima di $4.6M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.